Syros Pharmaceuticals,Inc. (NASDAQ:SYRS) Files An 8-K Other EventsItem 8.01 Other Events.
On December10, 2017, Syros Pharmaceuticals,Inc. issued a press release announcing data from its Phase 2 clinical trial evaluating SY-1425 (tamibarotene) in genomically defined subsets of patients with acute myeloid leukemia and myelodysplastic syndrome. A copy of this press release is filed as Exhibit99.1 to this Form8-K and incorporated herein by reference. The information contained on websites referenced in this press release is not incorporated herein.
Item 9.01 Financial Statements and Exhibits.
|
ExhibitNo.
|
Description
|
|
99.1
|
Press release dated December10, 2017.
|
Syros Pharmaceuticals, Inc. ExhibitEX-99.1 2 a17-28230_1ex99d1.htm EX-99.1 Exhibit 99.1 Syros Announces Initial Clinical Data from Ongoing Phase 2 Trial of SY-1425 Showing Biological and Clinical Activity as Single Agent in Genomically Defined AML and MDS Patients Clinical Activity Observed in 43% of Evaluable Relapsed or Refractory AML and Higher-Risk MDS Patients,…To view the full exhibit click here
About Syros Pharmaceuticals,Inc. (NASDAQ:SYRS)
Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines. The Company’s drug programs include SY-1425 (retinoic acid receptor alpha (RARa) agonist) and SY-1365 (cyclin-dependent kinase 7 (CDK7) inhibitor). SY-1425 (tamibarotene) is an oral, potent and selective agonist, or activator, of the transcription factor RARa. SY-1365 is a small molecule inhibitor of the transcriptional kinase known as CDK7. The Company is using its platform to analyze gene expression programs across additional cancers, inflammatory diseases and other diseases to identify optimal points of therapeutic intervention in specific subsets of patients.